# Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

> **NCT02777671** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 20 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** BIA 2-093
- **DRUG:** Gliclazide

## Key facts

- **NCT ID:** NCT02777671
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02777671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02777671, "Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02777671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*